Connect with us

Headlines

EternaTear Raises $4.9M in Funding

It’s developing a product for dry eye syndrome.

mm

Published

on

EternaTear, a startup company based in Raleigh, NC, has raised $4.9 million in funding, according to the North Carolina Biotechnology Center.

The company is working on a non-prescription product called EternaTear. It is an eyedrop intended to treat dry eye syndrome.

The Series A investment round was led by Carolina Angel Network and Keiretsu Forum, the North Carolina Biotechnology Center reports. Other investors included Band of Angels, Deep Work Capital, Duke Angel Network, Keiretsu Capital and various ophthalmologists, optometrists and others.

Tim Willis, CEO of EternaTear, was quoted saying that the funding “provides us the capital to develop our product for both the U.S. and European markets to help the 320 million globally who suffer from dry eye.”

The company’s immediate priorities include “completion of a multi-site clinical marketing study and U.S. Food and Drug Administration OTC registration,” according to the North Carolina Biotechnology Center.

Advertisement

Since launching in 2014, INVISION has won 23 international journalism awards for its publication and website. Contact INVISION's editors at [email protected].

SPONSORED VIDEO

SPONSORED BY ESSILOR

Introducing CrizalⓇ Rock™

Did you know three out of four people wipe their lenses on their clothes?* Or that one out of three people accidentally drop their glasses at least once a week?* It's no surprise, then, that 93 percent of wearers consider scratch-resistance an important characteristic when choosing lenses.* To prove the durability of new Crizal Rock lenses, we ran tests inspired by real life situations. To learn more about new Crizal Rock, the most scratch-resistant Crizal No-Glare lenses ever made, visit EssilorPRO.com/Crizal-Rock. *Study conducted by ⒸIpsos – Risky behaviors of eyeglass wearers - consumer quantitative research 2019 - declarative results - USA - n= 2345 eyeglass wearers

Promoted Headlines

Most Popular